Rituximab (Mabthera®) is a genetically engineered chimeric murine/human monoclonal antibody specific to CD20. CD20 is an approximately 35 KDa transmembrane phosphoprotein involved in the activation, proliferation, and differentiation of B-lymphocytes. It is absent in terminally differentiated plasma cells. The Fab domain of rituximab binds to the CD20 antigen on B-lymphocytes and the Fc domain recruits immune effector functions to induce apoptosis in B cells and is used in the trea™ent of leukemia s and lymphomas, some autoimmune disorders, and organ transplant. BioVision’s BioSim™ Rituximab ELISA kit is designed to quantify/measure the Rituximab with high specificity and sensitivity in biological matrices.
产品特点
• Easy, convenient, sensitive and time-saving method to measure the level of Rituximab in human serum and plasma.
• Detection Range: 3 - 300 ng/ml
• Sensitivity: 3 ng/ml
• Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
• Cross Reactivity: No significant cross-reactivity or interference with other proteins present in native human serum or other therapeutic immunoglobulins.
• Recovery rate: 85 – 115% with normal human serum samples with known concentrations
